1. Home
  2. GNPX vs MITQ Comparison

GNPX vs MITQ Comparison

Compare GNPX & MITQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$1.81

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Logo Moving iMage Technologies Inc.

MITQ

Moving iMage Technologies Inc.

HOLD

Current Price

$0.61

Market Cap

6.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
MITQ
Founded
2009
N/A
Country
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
6.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GNPX
MITQ
Price
$1.81
$0.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
835.5K
24.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.71
$0.50
52 Week High
$55.00
$1.66

Technical Indicators

Market Signals
Indicator
GNPX
MITQ
Relative Strength Index (RSI) 37.31 33.74
Support Level $1.90 $0.62
Resistance Level $2.29 $0.79
Average True Range (ATR) 0.28 0.05
MACD -0.05 -0.01
Stochastic Oscillator 2.26 15.20

Price Performance

Historical Comparison
GNPX
MITQ

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About MITQ Moving iMage Technologies Inc.

Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.

Share on Social Networks: